PDSB News and Press, PDS Biotechnology Corporation From 01/05/22

FLORHAM PARK, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that its ...

FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the reopening ...

PDS Biotechnology reported 3Q21 loss of $6.9 million or $(0.24) per share, compared with our estimated loss of $6.1 million or $(0.21) per share. The company held a conference call in which it reviewed two licensing agreements announced earlier in November 2021. These products advance the pipe...

The following slide deck was published by PDS Biotechnology Corporation in conjunction with their 2021 Q3 earnings call. For further details see: PDS Biotechnology Corporation 2021 Q3 - Results - Earnings Call Presentation

PDS Biotechnology Corporation (PDSB) Q3 2021 Results Conference Call November 10, 2021 08:00 AM ET Company Participants Deanne Randolph - Vice President of Commercial Development Frank Bedu-Addo - Chief Executive Officer Matthew Hill - Chief Financial Officer Lauren Wood - Chief Medical Offic...

PDS Biotechnology (NASDAQ:PDSB): Q3 GAAP EPS of -$0.24 misses by $0.04. Cash and cash equivalents as of September 30, 2021, were $69.74M. Shares +1.22% PM. Press Release For further details see: PDS Biotechnology EPS misses by $0.04

FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techn...

PDS Biotechnology (NASDAQ:PDSB) is scheduled to announce Q3 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward. For fur...

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

PDS Biotechnology (NASDAQ:PDSB) announces a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP). The worldwide, n...